The Therapeutic Catalyst supports the early translation of high-impact cancer research discoveries into novel therapeutics. The scheme funds projects with strong therapeutic potential across all cancer types, aiming to de-risk early ideas and validate targets or technologies. Projects are executed collaboratively between the academic researcher and Cancer Research Horizons drug discovery labs.
Eligibility Criteria:
-
Open to academic researchers worldwide
-
Must have an independent lab at a university or research institute
-
Suitable for early career, mid-career, established researchers, and clinicians
-
Projects must fall within the scheme’s drug discovery scope
Funding Details:
-
Up to £250,000 (USD 310,000) per project
-
Funding period: Up to 18 months
-
Covers academic staff time and research-related expenses
-
Funded activities may include assays, target validation, and early therapeutic feasibility studies
Deadline:
-
Expression of Interest deadline: 06 June 2025
-
3 application rounds annually: February, June, October
-
Contact the Therapeutic Catalyst team early for discussion and feedback
More Information: